New pill for itchy skin conditions enters early human testing

NCT ID NCT06982352

Recruiting now Symptom relief Sponsor: LAPIX Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 27 times

Summary

This early-stage study tests the safety of an experimental oral drug, LPX-TI641, in 48 adults with atopic dermatitis (eczema) or psoriasis. Participants take the drug or a placebo daily for 28 days. The main goal is to check for side effects and how the drug moves through the body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Clinical Investigations of Texas
RECRUITING

Dallas, Texas, 75075, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Red River Research Partners
RECRUITING

Fargo, North Dakota, 58103, United States
Triumpharma Clinical Research Unit at AlEssra Hospital
RECRUITING

Amman, Jordan, B204, Jordan

Conditions

Explore the condition pages connected to this study.

ATOPIC DERMATITIS (AD) PSORIASIS (PSO)